Evidence suggests that CD8 + T lymphocytes are involved in the control of human immunodeficiency
virus (HIV) infection in vivo, either by cytolytic mechanisms or by the release of HIV-…

Background In the RV144 trial, the estimated efficacy of a vaccine regimen against human
immunodeficiency virus type 1 (HIV-1) was 31.2%. We performed a case–control analysis to …

The ability of CD8 + T cells derived from human immunodeficiency virus (HIV)–infected
patients to produce soluble HIV–suppressive factor(s) (HIV–SF) 1–3 has been suggested as an …

Approximately 80 percent of all human sera that react with antigens of HTLV-III, the etiologic
agent of the acquired immune deficiency syndrome (AIDS), recognize protein bands at 66 …

Radiolabeled amino acid sequencing was used to characterize gp41, an antigen of HTLV-III/LAV,
the virus believed to be the etiological agent of the acquired immune deficiency …

The HIV-1 envelope glycoprotein (Env) undergoes conformational transitions consequent to
CD4 binding and coreceptor engagement during viral entry. The physical steps in this …

To test the hypothesis that β-chemokine levels may be relevant to the control of HIV in vivo,
we compared RANTES, MIP-1α, and MIP-1β production from purified CD8 + T cells from 81 …

A guiding principle for HIV vaccine design has been that cellular and humoral immunity work
together to provide the strongest degree of efficacy. However, three efficacy trials of Ad5-…

The RV144 vaccine trial implicated epitopes in the C1 region of gp120 (A32-like epitopes) as
targets of potentially protective antibody-dependent cellular cytotoxicity (ADCC) responses. …

The quest for a prophylactic AIDS vaccine is ongoing, but it is now clear that the successful
vaccine must elicit protective antibody responses. Accordingly, intense efforts are underway …